Your browser doesn't support javascript.
loading
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis.
Nash, Peter; Vanhoof, Johan; Hall, Stephen; Arulmani, Udayasankar; Tarzynski-Potempa, Rita; Unnebrink, Kristina; Payne, Andrew N; Cividino, Alfred.
Afiliación
  • Nash P; Department of Medicine, University of Queensland Rheumatology Research Unit Sunshine Coast, Queensland, Australia. drpnash@tpg.com.au.
  • Vanhoof J; Department of Rheumatology, ReumaClinic Genk, Genk, Belgium.
  • Hall S; Department of Medicine, Monash University, Cabrini Health, Malvern, Australia.
  • Arulmani U; Immunology Clinical Development, AbbVie, North Chicago, IL, USA.
  • Tarzynski-Potempa R; Biotherapeutics, Global Medical Affairs, AbbVie, Lake Bluff, IL, USA.
  • Unnebrink K; Data and Statistical Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
  • Payne AN; Immunology Clinical Development, AbbVie, North Chicago, IL, USA.
  • Cividino A; Department of Medicine, McMaster University, Ontario, Canada.
Rheumatol Ther ; 3(2): 257-270, 2016 Dec.
Article en En | MEDLINE | ID: mdl-27747583
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Rheumatol Ther Año: 2016 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Rheumatol Ther Año: 2016 Tipo del documento: Article País de afiliación: Australia